AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02843334 — intervention group
Intervention type: BIOLOGICAL
Intervention: Dried blood spot (DBS) sampling
Description: DBS be collected during a hemodialysis session and deposited on an anonymized blotting paper. Laboratory ARCHIMED Life Science GmbH, based in Austria will perform all the biological analysis. For the diagnosis, men will have a measure of the alpha-galactosidase activity level, whereas screening in women will be established on the association of alpha-galactosidase activity and lyso-GB3 analyses. If results are compatible, genetic mutation will be searches in order to confirm the diagnosis for women.
Study NCT03695991 — intervention group
Intervention type: PROCEDURE
Intervention: percutaneous nephrostomy
Description: The percutaneous nephrostomy will be done under sonographic or fluoroscopic guidance. Establishment of intravenous access and antibiotics will be performed half an hour prior to procedure particularly in patients presenting with urinary tract infection. The procedure will be done under local anesthesia but general anesthesia may be used for uncooperative patients. percutaneous nephrostomy will be performed in the prone position, however, in case of relative contraindication to prone position
Study NCT01884532 — intervention group
Intervention type: DEVICE
Intervention: ASR-XL Metal-on-Metal
Description: All patients that are post-operative will have undergone total hip arthroplasty with the ASR-XL Metal-on-Metal device.
Study NCT04384783 — intervention group
Intervention type: DRUG
Intervention: growth hormone
Description: growth hormone was adjuvanted 2IU/d from previous menstrual period for about six weeks.
Study NCT04715425 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracoscopic pulmonary vein isolation without additional lesion + left atrial appendage exclusion/amputation
Description: Bilateral pulmonary vein isolation using radiofrequency energy
Study NCT04715425 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter pulmonary vein isolation without additional lesions
Description: Bilateral pulmonary vein isolation using radiofrequency energy
Study NCT03836599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad
Description: Participants will receive verinurad 24 mg in cohort 1 and 12 mg in cohort 2 once daily.
Study NCT03836599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Participants will receive allopurinol 300 mg once daily.
Study NCT03836599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During Run-in Period, participants in cohort 1 will receive placebo matching allopurinol capsule once daily from Day -7 to Day -1. During treatment period, participants in cohort 1 will receive placebo matching allopurinol capsule and placebo matching verinurad capsule once daily from Day 1 to Day 7.
Study NCT03116360 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic Ultrasound
Description: The physician performing the ultrasound will be blinded to the results of the x-ray and MRI. The physician performing the ultrasound will be informed of the bone in question (ex. Tibia) and will be able to perform a focused history and exam. The bone in which acute stress fracture is suspected will then be scanned throughout its length in two orthogonal views. The criteria for diagnosing acute stress fracture on ultrasound include displaying 2 out of 3 of the following: hypoechoic periosteal elevation of cortical bone, visible cortical disruption, hyperemia surrounding the periosteal lesion on power Doppler. The ultrasound physician will then be asked to make a determination whether the ultrasound study is positive for acute stress fracture or negative/indeterminate.
Study NCT00002946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: penclomedine
Study NCT03659539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PROPOFOL
Description: Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
Study NCT03659539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: Desflurane delivery will be controlled using a agent specific vaporiser. The dial concentration of the vaporiser will be adjusted to maintain a BIS of 50-55 in the patients.
Study NCT02202187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944
Description: Investigational Study Drug
Study NCT02202187 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03034434 — intervention group
Intervention type: DEVICE
Intervention: Trans-vaginal ultrasound
Description: Three trans-vaginal ultrasounds, the 1st to be performed 8 hours post delivery, the 2nd 24 hours after delivery and the 3rd 48 hours after delivery.
Study NCT00955721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenously (IV) on Day 1 of each 14 day cycle, until progression or unacceptable toxicity develops.
Study NCT01250431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EFT (Emotional Freedom Techniques)
Description: 10 EFT sessions
Study NCT01792648 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard reference diet
Description: 50% energy as carbohydrate, 15% energy as protein, 35% energy as total fat
Study NCT01792648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almond supplemented diet
Description: 50% energy as carbohydrate, 15% energy as protein, 35% energy as total fat, 20% energy from almonds
Study NCT01792648 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low carbohydrate reference diet
Description: 26% energy from carbohydrate, 29% energy from protein, 45% energy from total fat
Study NCT03782558 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical transection of transverse ligament
Description: Standard therapy for CTS. An incision is made at the base of the palm of the hand. Then the transverse ligament is cut, which releases the compression of the median nerve and improves the symptoms.
Study NCT02375516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention Program
Description: Youths in the intervention-arm will interact online with the initial intervention program between pretest and posttest measurement occasions and will interact with booster sessions subsequent to 1- and 2-year follow-up measurement occasions. Owing to the expense associated with developing a treatment-as-usual intervention for computer delivery in the control arm, youths assigned to the control arm will receive no intervention.
Study NCT05019781 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic tape
Description: Tape was applied to sternocleidomastoid, upper trapezius, deltoid, flexor palmaris longus muscles as suggested by Kase et al. (Kase, Wallis, Kase, \& Association, 2003). The tape was applied to the left side of the participants while sitting position because the violin is traditionally played by placing it on the left shoulder, balancing the neck using the left hand, and bowing with the right arm.
Study NCT05019781 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tape
Description: The placebo tape was applied transverse to the muscle groups in two levels (a point of 10 cm above to wrist and elbow) with no tension when the participants were sitting position with the shoulder flexed at 90°, and the elbow flexed at 90°.
Study NCT03103412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-3504
Description: TD-3504
Study NCT03103412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15N2-tofacitinib
Description: 15N2-tofacitinib
Study NCT00955721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Intravenously (IV) on Day 2 of each 14 day cycle, until progression or unacceptable toxicity develops.
Study NCT00955721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Orally, twice daily for each 14-day cycle, until progression or unacceptable toxicity develops.
Study NCT04344405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: vitamin D supplementation
Study NCT01447784 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal injection 1 x 11 administrations 4 weeks apart
Study NCT02692027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Same-day ART initiation
Description: Participants tested HIV-positive during community-based HIV testing and randomized to the intervention group receive post-test counseling and on-the-spot clinical and laboratory assessment. Directly after the positive HIV-test result the study nurse assesses the participant clinically and performs point-of-care laboratory baseline testing. Thereafter, the participant receives a standardized short adherence counselling. After adherence counseling the participant is offered to start ART immediately. Those who decide to start ART during the visit or intend to start within seven days will receive a 30 day ART-supply and an follow-up appointment at the clinic within 12 to 16 days.~In order to reduce travel time and transport cost, participants who are clinically stable, will have their follow-up visits and ART refills more widely spaced with appointments at 6 weeks, 3, 6, (9) and 12 months after ART initiation.
Study NCT02692027 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Individuals found HIV-positive during the community-based HIV testing campaigns and randomized to the control arm receive post-test counselling and a referral letter with an appointment at their chosen health facility. On the first visit to the clinic, the participant receives laboratory assessment and a first adherence counselling session. The participant must then return to the clinic to receive his/her laboratory results and to undergo a second adherence counselling session.~Once the participant has started ART, the first and second follow-up visits are scheduled for 14 and 28 days after ART initiation, respectively. Thereafter, follow-up visits are scheduled monthly until 6 months after ART initiation. If the participant is clinically stable, clinical follow-up visits may then be spaced to 3-monthly intervals, but refills of ART must still be collected on a monthly basis.
Study NCT00460213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 80mg daily
Study NCT00460213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 160mg daily
Study NCT04580550 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Axial length variability
Description: Biometry (axial length measurement)is performed using the IOL Master 700 (Carl Zeiss Meditec AG, Jena, Germany) and Heidelberg Anterion (Heidelberg Engineering, Germany) pre and postoperatively.
Study NCT03018873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning （RIPC）
Description: once RIPC: three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg.
Study NCT03018873 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: remote ischemic preconditioning （RIPC）
Description: once RIPC: three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg.
Study NCT03254784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Capsule
Description: Oral capsule
Study NCT03254784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Tablet
Description: Oral tablet
Study NCT04521374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preload meals that are solid or texture modified and are fortified with protein or not fortified with protein
Description: Immediately after consuming the preload meal, volunteers will use a 100mm visual analogue scale (VAS) to rate their liking towards the meal, their hunger, fullness, desire to eat and prospective food intake. Subsequently, they will record these every 30 minutes until they consume their ad-libitum dinner
Study NCT03466151 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
Description: Treatment of subjects eligible for percutaneous transluminal coronary angioplasty (PTCA) as per study requirements
Study NCT03466151 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System
Description: Treatment of subjects eligible for percutaneous transluminal coronary angioplasty (PTCA) as per study requirements
Study NCT03014258 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NF54 P. falciparum malaria challenge
Description: Aseptically-raised A. stephensi female mosquitoes infected with aseptically-raised P. falciparum parasites of the NF54 strain.
Study NCT03014258 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NF54 P. falciparum malaria challenge
Description: Aseptically-raised A. stephensi female mosquitoes infected with aseptically-raised P. falciparum parasites of the NF54 strain.
Study NCT00982280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol PR
Description: Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg, 100 mg or 150 mg Tapentadol PR twice daily, adjusting at 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed 500 mg of Tapentadol per day.~Maintenance Period: Participants continuing on the dose established in the previous period.
Study NCT01121757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Azacitidine 75 mg/m2 SC or IV on days 1-5; subjects will begin Part 2 at the azacitidine dose level tolerated in Part 1a.
Study NCT01121757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Lenalidomide dose is 15mg po per day on days 1-21; starting dose during Part 2 will depend upon how well the subject tolerated drug during Part 1.
Study NCT03773484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opioid naive
Description: Visit where the order is for an included opioid and there is no prior opioid prescription with a start date of greater than 1 day and less than 91 days
Study NCT03773484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: At-risk for long term use
Description: Visit where the order is for an included opioid, there is a prior opioid prescription with a start date greater than 1 day and less than 91 days, and there is no prior opioid prescription with a start date greater than 90 days
Study NCT03773484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Long-term opioid recipient
Description: Total opioid doses are at least 50 MME per day, there are two or more prior opioid prescriptions with two different start dates both greater than 1 day and less than 91 days, and there is a prior opioid prescription with a start date greater than 90 days and less than 181 days
Study NCT00928772 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRANIAL ELECTROTHERAPY (Alpha Stim) + SHAM MIDAZOLAM
Description: APPLYING OF ELECTRODES ON THE EAR LOBES AND TEMPLES WHICH ARE SENDING AN ACTIVE MICROCURRENT THROUGH THE MIDBRAIN PRODUCING SEDATION WITHOUT PHARMACOLOGICAL AGENTS AND GIVING NORMAL SALINE AS A SHAM DRUG SEDATION
Study NCT00928772 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: MIDAZOLAM + SHAM ELECTRODES SIMULATING CRANIAL ELECTROTHERAPY
Description: CONVENTIONAL METHOD OF PERIOPERATIVE SEDATION
Study NCT00928772 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NO SEDATION WITH SHAM CRANIAL ELECTROSTIMULATION AND PLACEBO VERSED
Description: NO ACTIVE SEDATION, ONLY SHAM ELECTRODES AND NORMAL SALINE SIMULATING MIDAZOLAM.
Study NCT02985723 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AT LISA tri toric 939MP
Study NCT05032586 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wearing virtual reality headsets
Description: When the patient adapted to the headset and started to play games, he was taken to the dressing room with the VR headset and the application continued until the process was completed. Before starting the study, a pilot study was conducted to determine the time to wear headsets in ten children. It was observed that the children who were taken to the dressing room without wearing VR headsets refused to wear it. In order to prevent the child from experiencing anxiety in the dressing room, the child was put on VR headset in the patient room and then taken to the dressing room. After the procedure was completed, the VR headset was removed and the patient's oxygen saturation and heart rate were recorded on the Application Registration Form. The patients were asked regarding the pain and anxiety levels felt during dressing before and after the procedure and marked on the Wong Baker Scale, State-Trait Anxiety Inventory for Children and Children's Fear Scale.
Study NCT02239237 — intervention group
Intervention type: DRUG
Intervention: Compound Kuh-seng Injection
Description: Compound Kuh-seng Injection is a kind of natural compound injection extracted from Chinese herbs Kuh-seng (Radix Sophorae Flavescentis) and Rhizoma Heterosmilacis Japonicae. The major bioactive ingredients include oxymatrine，sophocarpidine, matrine, flavonoid etc.
Study NCT00408629 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Prefilled syringe, 40 mg, 160 mg at Week 0, 80 mg at Week 2, and 40 mg every other week between Weeks 4 and 50.
Study NCT00408629 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching Placebo for prefilled syringe, 40 mg,
Study NCT00547573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 10 mg tadalafil tablet taken by mouth as needed for 12 weeks not more than once a day
Study NCT00547573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 20 mg tadalafil tablet taken by mouth as needed for 12 weeks not more than once a day
Study NCT00547573 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet taken by mouth as needed for 12 weeks not more than once a day
Study NCT00282100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefetinib (Iressa)
Study NCT03878589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin (OT)
Description: During the 4 week intervention, participants will self-administer twice daily 24 International Units intranasal oxytocin (OT) and will be contacted once a week for assessment of adverse effects and for download of the smartwatch data. During the last week of the intervention period, three assessment sessions will follow that will be identical to the baseline sessions.
Study NCT03878589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (P)
Description: During the 4 week intervention, participants will self-administer twice daily 24 International Units intranasal placebo (P) and will be contacted once a week for assessment of adverse effects and for download of the smartwatch data. During the last week of the intervention period, three assessment sessions will follow that will be identical to the baseline sessions.
Study NCT03854474 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT03854474 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT03854474 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03854474 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT04799574 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: music therapy activities
Description: Music therapy activity course design (Protocol):~The researchers in this study are the leaders of the activities and the nurses who had completed training in music therapy courses and obtained a senior music activity leadership certificate and qualification, such as books and internship certificates. The course design uses the percussion music theory and Dalcroze and Orpff music pedagogy to plan activities, as follows:~Each class in the music therapy activity course design has a fixed process. The 90-minute course includes 10-15 minutes of warm-up activities, 50-60 minutes of main activities, 10-15 minutes of recovery activities, and 10 minutes of rest for the elders in the middle. The content of the weekly main activities uses different music, musical instruments, props, or rhythms to lead the rhythm music activities.
Study NCT04799574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music therapy activities
Description: Music therapy activity course design (Protocol):~The researchers in this study are the leaders of the activities and the nurses who had completed training in music therapy courses and obtained a senior music activity leadership certificate and qualification, such as books and internship certificates. The course design uses the percussion music theory and Dalcroze and Orpff music pedagogy to plan activities, as follows:~Each class in the music therapy activity course design has a fixed process. The 90-minute course includes 10-15 minutes of warm-up activities, 50-60 minutes of main activities, 10-15 minutes of recovery activities, and 10 minutes of rest for the elders in the middle. The content of the weekly main activities uses different music, musical instruments, props, or rhythms to lead the rhythm music activities.
Study NCT03103412 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00741988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: ixabepilone 30 mg/m2